Centers for Disease Control and Prevention, National Center for HIV/Hepatitis/STD/TB Prevention, Division of Viral Hepatitis, Atlanta, GA 30333, USA.
Virus Res. 2011 Oct;161(1):84-92. doi: 10.1016/j.virusres.2011.06.006. Epub 2011 Jun 15.
Development of accurate diagnostic assays for the detection of serological markers of hepatitis E virus (HEV) infection remains challenging. In the course of nearly 20 years after the discovery of HEV, significant progress has been made in characterizing the antigenic structure of HEV proteins, engineering highly immunoreactive diagnostic antigens, and devising efficient serological assays. However, many outstanding issues related to sensitivity and specificity of these assays in clinical and epidemiological settings remain to be resolved. Complexity of antigenic composition, viral genetic heterogeneity and varying epidemiological patterns of hepatitis E in different parts of the world present challenges to the refinement of HEV serological diagnostic assays. Development of antigens specially designed for the identification of serological markers specific to acute infection and of IgG anti-HEV specific to the convalescent phase of infection would greatly facilitate accurate identification of active, recent and past HEV infections.
开发准确的诊断检测方法以检测戊型肝炎病毒 (HEV) 血清学标志物仍然具有挑战性。自 HEV 发现以来的近 20 年中,在鉴定 HEV 蛋白的抗原结构、工程高度免疫原性的诊断抗原以及设计有效的血清学检测方法方面取得了重大进展。然而,在临床和流行病学环境中,这些检测方法的敏感性和特异性方面仍存在许多悬而未决的问题。抗原组成的复杂性、病毒遗传异质性以及世界各地戊型肝炎的不同流行模式,给 HEV 血清学诊断检测方法的改进带来了挑战。开发专门用于鉴定急性感染特异性血清学标志物的抗原以及 IgG 抗-HEV 特异性的感染恢复期抗原,将极大地促进对活跃、近期和过去的 HEV 感染的准确识别。